DUARTE, Calif.--(BUSINESS WIRE)--City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, today announced that it has licensed intellectual property relating to its pioneering chlorotoxin chimeric antigen receptor (CLTX-CAR) T cell therapy to Chimeric Therapeutics Limited, an Australian biotechnology company.
The therapy is currently being used in a phase 1 clinical trial at City of Hope to treat glioblastoma (GBM), a type of brain tumor. The first patient in the trial was recently dosed; Behnam Badie, M.D., chief of City of Hopes Division of Neurosurgery and The Heritage Provider Network Professor in Gene Therapy, is leading this innovative, first-of-its-kind trial.
Chimeric has acquired the exclusive worldwide rights to develop and commercialize certain patents relating to City of Hopes CLTX-CAR T cells, as well as to further develop the therapy for other cancers.
City of Hope is excited to enter into this agreement with Chimeric as it supports our innovative research in CAR T cell therapy and our commitment to extend these therapies to more patients, particularly those with GBM and other solid tumors that are difficult to treat, said Christine Brown, Ph.D., The Heritage Provider Network Professor in Immunotherapy and deputy director of City of Hopes T Cell Therapeutics Research Laboratory. Chimeric shares our goal of providing effective CAR T cell therapies to more patients with current unmet medical needs.
Led by Brown and Michael Barish, Ph.D., chair of City of Hopes Department of Developmental and Stem Cell Biology, and Dongrui Wang, Ph.D., a recent graduate of City of Hopes Irell & Manella Graduate School of Biological Sciences, the team developed and tested the first CAR T cell therapy using CLTX, a component of scorpion venom, to direct T cells to target brain tumor cells. The research was published this past March in Science Translational Medicine.
Chimeric is excited to join City of Hope in its quest to find more effective cancer therapies. This is an exceedingly rare opportunity to acquire a promising technology in one of the most exciting areas of immuno-oncology today, said Paul Hopper, executive chairman of Chimeric. Furthermore, the CLTX-CAR T cell therapy has completed years of preclinical research and development, and recently enrolled its first patient in a phase 1 clinical trial for brain cancer.
CARs commonly incorporate a monoclonal antibody sequence in their targeting domain, enabling CAR T cells to recognize antigens and kill tumor cells. In contrast, the CLTX-CAR uses a synthetic 36-amino acid peptide sequence first isolated from death stalker scorpion venom and now engineered to serve as the CAR recognition domain.
In this recent study, City of Hope researchers used tumor cells in resection samples from a cohort of patients with GBM to compare CLTX binding with expression of antigens currently under investigation as CAR T cell targets. They found that CLTX bound to a greater proportion of patient tumors, and cells within these tumors.
CLTX binding included the GBM stem-like cells thought to seed tumor recurrence. Consistent with these observations, CLTX-CAR T cells recognized and killed broad populations of GBM cells while ignoring nontumor cells in the brain and other organs. The study team demonstrated that CLTX-directed CAR T cells are highly effective at selectively killing human GBM cells without off-tumor targeting and toxicity in cell-based assays and in animal models.
City of Hope, a recognized leader in CAR T cell therapies for GBM and other cancers, has treated more than 500 patients since its CAR T program started in the late 1990s. The institution continues to have one of the most comprehensive CAR T cell clinical research programs in the world it currently has 30 ongoing CAR T cell clinical trials, including CAR T cell trials for HER-2 positive breast cancer that has spread to the brain, and PSCA-positive bone metastatic prostate cancer. It was the first and only cancer center to treat GBM patients with CAR T cells targeting IL13R2, and the first to administer CAR T cell therapy locally in the brain, either by direct injection at the tumor site, through intraventricular infusion into the cerebrospinal fluid, or both. In late 2019, City of Hope opened a first-in-human clinical trial for patients with recurrent GBM, combining IL13R2-CAR T cells with checkpoint inhibitors nivolumab, an anti-PD1 antibody, and ipilimumab, blocking the CTLA-4 protein.
Both an academic medical center and a drug development powerhouse, City of Hope is known for creating the technology used in the development of human synthetic insulin and numerous breakthrough cancer drugs. Its unique research and development hybrid of the academic and commercial creates an infrastructure that enables City of Hope researchers to submit an average of 50 investigational new drug applications to the U.S. Food and Drug Administration each year. The institution currently holds more than 450 patent families.
"City of Hope is delighted to license this technology to Chimeric, said Sangeeta Bardhan Cook, Ph.D., City of Hope director of the Office of Technology Licensing. We are impressed with the ability of their executive team to push and bring therapies to market expeditiously. At City of Hope, our mission is to transform the future of health care. We believe Chimeric has the vision to offer innovative therapies to cancer patients.
About City of Hope
City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hopes translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin and numerous breakthrough cancer drugs are based on technology developed at the institution. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope has been ranked among the nations Best Hospitals in cancer by U.S. News & World Report for 14 consecutive years. Its main campus is located near Los Angeles, with additional locations throughout Southern California. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.
See more here:
- New Drug Could Improve Effectiveness of Stem Cell Therapy - Pain News Network - December 1st, 2020
- Hematologist/Stem Cell Biologist to Direct Hematology and Cellular Therapy at Cedars-Sinai - Newswise - December 1st, 2020
- Experimental stem cell gene therapy may give a new lease of life for patient with sickle cell disease - News-Medical.Net - December 1st, 2020
- Coronavirus Updates: The Latest Treatments and Vaccines - GovTech - December 1st, 2020
- Hematologist Discusses the Impact a Myeloma CAR T-Cell Approval Would Have on the Treatment Landscape - DocWire News - December 1st, 2020
- ONLINE: The UW Now - Isthmus - December 1st, 2020
- Exploring the Challenges and Opportunities of Harvesting CTCs - Technology Networks - December 1st, 2020
- Mustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - GlobeNewswire - December 1st, 2020
- Celularity Announces Positive DMC Safety Review and Continuation of its Phase I/II CYNK-001-COVID-19 (CYNKCOVID) Study - PRNewswire - December 1st, 2020
- COVID-19 patients on some cancer therapies may be contagious for months: study - Reuters - December 1st, 2020
- Gain Therapeutics and University of Maryland School of Medicine Announce Research Collaboration - GlobeNewswire - December 1st, 2020
- Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine - GlobeNewswire - November 30th, 2020
- Coronavirus treatments and vaccines. Here are the latest developments - San Francisco Chronicle - November 30th, 2020
- Stem Cell Assay Market Research Report: Industrial Chain, Sourcing Strategy and Downstream Buyers with Forecast 2026 - Cheshire Media - November 30th, 2020
- Human Embryonic Stem Cell (hESC) Market Research Report 2020 with Manufacturing Process Analysis and Market Concentration Rate till 2026 - The Market... - November 30th, 2020
- Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes - Philippine Canadian... - November 30th, 2020
- California's stem cell research agency looks to the future - Bond Buyer - November 26th, 2020
- Scientists Reveal a New Drug That Directs Stem Cells To Desired Sites - Science Times - November 26th, 2020
- Growing Value of Stem Cells in Medicine to Create a US$2,4 Billion Opportunity for Induced Pluripotent Stem Cell ((iPSC) - GlobeNewswire - November 26th, 2020
- Celularity Announces Dosing of First Patient in Phase I Study of Human Placental Hematopoietic Stem Cell-Derived Natural Killer Cells (CYNK-001) in... - November 26th, 2020
- Unexpected discovery about stem cell immortality study - News - The University of Sydney - November 26th, 2020
- 'The hope is that is works': Coliseum participates in clinical trial for COVID-19 recovery - wgxa.tv - November 26th, 2020
- Growing at an annualized rate of over 16.5%, the cell therapy manufacturing market is estimated to reach close to USD 11 Billion by 2030, claims Roots... - November 26th, 2020
- Global Cell Harvesting Market to Reach US$381,4 Million by the Year 2027 - PRNewswire - November 26th, 2020
- Novel CAR T-cell therapy shows promising early results in children with neuroblastoma - News-Medical.Net - November 26th, 2020
- Our turbulent debates on medicine and morals - The Irish Catholic - November 26th, 2020
- Impact of COVID 19 on Orthopedic Regenerative Medicine Market Detailed Research Study 2020-2027 | Curasan, Inc., Carmell Therapeutics Corporation,... - November 26th, 2020
- Novartis Invests in Stem Cell Therapy for Covid - BloombergQuint - November 20th, 2020
- California's Stem Cell Agency Will Get A Funding Boost From Prop 14. Here's A Look At Its History. - Capital Public Radio News - November 20th, 2020
- Fred Hutch at ASH: Fauci fireside chat, latest on cell therapies, repairing immune function, COVID and clots and more - Newswise - November 20th, 2020
- Study reveals how smoking worsens SARS-CoV-2 infection in the airways - UCLA Newsroom - November 20th, 2020
- SEE | Smoking worsens Covid-19 infection in the airways, new study reveals - Health24 - November 20th, 2020
- In a First, Scientists Say They've Partially Reversed a Cellular Aging Process in Humans - ScienceAlert - November 20th, 2020
- ExCellThera to establish stem cell bioproduction facility creating up to 150 jobs thanks to Government of Canada support - Canada NewsWire - November 16th, 2020
- Stanford coach's quest to save his brother: 'God, I hope this works' - Scope - November 16th, 2020
- Athersys Announces Three Appointments to Board of Directors - Business Wire - November 16th, 2020
- Stem Cell Assay Market Will Generate Massive Revenue In Future: GE Healthcare, Promega Corporation, Thermo Fisher Scientific, Merck KGaA, Cell... - November 16th, 2020
- Meeting Agenda Focuses on Increased Applications of Cellular Therapies in Hematologic Cancers - Targeted Oncology - November 16th, 2020
- Leading Human Immunology and Infectious Disease Experts to Join UM School of Medicines Institute of Human Virology - Newswise - November 16th, 2020
- Stem cell therapy shows promise in treating COVID-19 - The Pharma Letter - November 11th, 2020
- FibroGenesis Announces the Filing of its 250th Patent for Fibroblast Cell Therapy Platform - PRNewswire - November 11th, 2020
- Angiocrine Bioscience Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to AB-205 (Universal E-CEL Cell Therapy) to... - November 11th, 2020
- Global Live Cell Imaging Markets, 2020-2025 - Growing Adoption of High-Content Screening Techniques in Drug Discovery - Yahoo Finance UK - November 11th, 2020
- Protective protein could help keep blood young and healthy - New Atlas - November 10th, 2020
- Worldwide Regenerative Medicine Industry to 2025 - Featuring Allergan, Amgen and Baxter International Among Others - PRNewswire - November 10th, 2020
- Dr. Braunschweig on Selecting Between Transplant and CAR T-Cell Therapy in DLBCL - OncLive - November 8th, 2020
- Global Regenerative Medicine Market (2020 to 2025) - Industry Trends, Share, Size, Growth, Opportunity and Forecast - ResearchAndMarkets.com -... - November 8th, 2020
- Editas Medicine Announces Third Quarter 2020 Results and Update - GlobeNewswire - November 8th, 2020
- Using telehealth to boost treatment for substance-use disorder - American Medical Association - November 4th, 2020
- Stem Cell and Regenerative Therapy Market Monitoring Growth Opportunities 2024 - Aerospace Journal - November 4th, 2020
- Regenerative Medicine Stem Cells Market Forecast Revised in a New FMI Report as COVID-19 Projected to Hold a Massive Impact on Sales in 2019 - KYT24 - November 4th, 2020
- Global Stem Cell Assay Market Growth, Size, Analysis, Outlook by 2020 Trends, Opportunities and Forecast to 2025 - Zenit News - November 4th, 2020
- Asia Pacific Cartilage Degeneration Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Procedure Type ; Application ; and End User and... - November 4th, 2020
- Asia Pacific Amniotic Membrane Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Enzyme ; Application ; End User, and Country -... - November 4th, 2020
- Minaris Regenerative Medicine to Significantly Expand Manufacturing Capacity for Cell and Gene Therapies in Germany and Japan - b3c newswire - November 2nd, 2020
- What Are the Treatment Options When Lymphoma Returns? - SurvivorNet - November 2nd, 2020
- Cell Banking Outsourcing Market: High Demand for Stem Cell Therapies to Trigger Growth of the Market - BioSpace - November 2nd, 2020
- How pain changes your brain - News - The University of Sydney - November 2nd, 2020
- Optimal Health: Cutting Edge Restorative Treatments Cityview - Knoxville City View - November 2nd, 2020
- New screening tool could turn up genes tied to developmental disorders - STAT - October 31st, 2020
- Outlook on the Regenerative Medicine Global Market to 2025 - Impact of COVID-19 on the Market - GlobeNewswire - October 31st, 2020
- Opinion: Proposition 14 Could Save the Life of Someone You Love - Times of San Diego - October 31st, 2020
- "Training" the immune system with -glucan compound may improve immune recovery - News-Medical.Net - October 31st, 2020
- Angelika Amon, cell biologist who pioneered research on chromosome imbalance, dies at 53 - MIT News - October 31st, 2020
- Novartis expands Kymriah manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia - GlobeNewswire - October 31st, 2020
- Global Induced Pluripotent Stem Cells (iPSCs) Market 2020 with COVID-19 After Effects Growth Drivers, Top Key Players, Industry Segments and Forecast... - October 29th, 2020
- Ways to cash in on regenerative medicine - The Australian Financial Review - October 29th, 2020
- We can't stand idly by: Vote 'yes' on Prop. 14 for stem cell research - The Jewish News of Northern California - October 29th, 2020
- Grant programs will provide $2.2 million to support biomedical research on healthy aging - News-Medical.Net - October 29th, 2020
- NK Cell Therapy and Stem Cell Therapy Market Insight | Strategic Industry Evolutionary Analysis Focus on Leading Key Players and Revenue Growth... - October 29th, 2020
- Baby Gets Early Stem Cell Transplant to Treat Rare Disease Thanks to Newborn Screening - University of Michigan Health System News - October 28th, 2020
- Exclusive: "Ending Disease" Documentary Explores How Stem Cell Therapy Aims to Cure the Incurable - Prevention.com - October 28th, 2020
- A New Piece Added to the Pituitary Gland Puzzle Revises Evolutionary History - Technology Networks - October 28th, 2020
- Proposition 14 Aims to Keep California at Worldwide Center of Stem Cell Research - Times of San Diego - October 18th, 2020
- Should California invest $5.5 billion more into promising stem cell research? - The Mercury News - October 14th, 2020
- Singapore invents digitized optimization of culture conditions for cell therapy - BSA bureau - October 14th, 2020
- Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease... - October 14th, 2020
- Marcus Neuroscience Institute names Khalid A. Hanafy, M.D., Ph.D., Medical Director of Neurocritical Care and Research - Baptist Health South Florida - October 14th, 2020
- Fact check: Trump's antibody therapy not made from fetal stem cells but fetal-derived cells used during testing - USA TODAY - October 12th, 2020
- Brain organoids reveal neuronal flaws in syndrome tied to autism - Spectrum - October 12th, 2020